High-Investment Medications – Proceedings from the AMCP Partnership Forum
As novel therapies to address important medical needs are approved, the high costs for these medications — especially cell and gene therapies — can raise sustainability and affordability concerns for employers, payers, and patients. To explore alternative payment models, financial tools, and policy initiatives to improve the predictability, affordability, and accessibility of high-investment treatments and ensure patients get the medications they need at a cost they can afford, AMCP held a multi-stakeholder Partnership Forum in Arlington, VA, April 26 and 27, 2022. Together the group:
1. Identified stakeholder challenges associated with high-investment medications.
2. Explored the challenges and opportunities related to financial tools to address predictability, affordability, and accessibility for high-investment medications, and;
3. Determined the challenges and opportunities of potential policy solutions to improve the predictability, affordability, and accessibility of high-investment treatments.
Moderator:
Jennifer S. Graff, PharmD
Sr. Director, Professional Affairs, AMCP
Speakers:
Brent Eberle, RPh, MBA
Sr. Vice President, Chief Pharmacy Officer
Navitus Health Solutions
Anne Jackson, FSA, MAAA
Principal and Consulting Actuary
Milliman, Inc
Erin Lopata, PharmD, MPH
Vice President, Access Experience Team
PRECISIONvalue
